DNA variants correlated with blood based biomarkers may predict disease features within COPD
By Sam LaBrie Developing precision medicines for COPD is an important goal, as the disease is the third most common cause of death in the developed...
Monitoring differences in the innate and adaptive immune response in Amish and Hutterite children
By Ralph McDade Let your kids get dirty; it’s good for them! In the current issue of the New England Journal of Medicine researchers explore the mec...
Researchers in this immuno-oncology trial used Myriad RBM’s services to measure serum biomarkers.
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma The data presented in this paper shows baseline and on-treatment biomarkers...
Impressions from Biomarkers and Diagnostics World Congress 2016
Our sales and marketing team represented Myriad RBM at the Biomarkers and Diagnostics World Congress in Philadelphia with a booth on the vendor floor....
Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia
An international team of researchers used Myriad RBM’s Multi-Analyte Profile (MAP) technology to identify a pattern of cardiometabolic biomarkers that...
ENRAGE: A Novel Inflammatory Marker for Incident Coronary Heart Disease
This recent paper in the Arteriosclerosis, Thrombosis and Vascular Biology Journal of the American Heart Association describes an interesting prospect...
Blood-based proteins are crucial to the development of biomarker tests aimed at improving the diagnosis and treatment of psychiatric disorders
A recent review of studies measuring proteins in blood serum/plasma illustrates the systemic nature of disease-related changes in patients with schizo...